Rinat Galiulin

895 total citations · 1 hit paper
7 papers, 556 citations indexed

About

Rinat Galiulin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Rinat Galiulin has authored 7 papers receiving a total of 556 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Immunology. Recurrent topics in Rinat Galiulin's work include Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Rinat Galiulin is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Lung Cancer Research Studies (3 papers) and Colorectal Cancer Treatments and Studies (2 papers). Rinat Galiulin collaborates with scholars based in United States, Russia and Poland. Rinat Galiulin's co-authors include Keunchil Park, Mircea Dediu, Tudor–Eliade Ciuleanu, H. Depenbrock, Martin Reck, Beatrix Bálint, Aleksandra Szczęsna, Mark A. Socinski, Nick Thatcher and Shivani Nanda and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and BioDrugs.

In The Last Decade

Rinat Galiulin

7 papers receiving 544 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

2015 331 citations Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Rinat Galiulin

Since Specialization

Citations

This map shows the geographic impact of Rinat Galiulin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rinat Galiulin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rinat Galiulin more than expected).

Fields of papers citing papers by Rinat Galiulin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rinat Galiulin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rinat Galiulin. The network helps show where Rinat Galiulin may publish in the future.

Co-authorship network of co-authors of Rinat Galiulin

This figure shows the co-authorship network connecting the top 25 collaborators of Rinat Galiulin. A scholar is included among the top collaborators of Rinat Galiulin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rinat Galiulin. Rinat Galiulin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

#	Work	Indexed citations
1	Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) 2021 ·BioDrugs ·Konstantinos Syrigos, (unknown), (unknown), Igor Bondarenko, Mikhail Dvorkin, (unknown), Rinat Galiulin, Vladimer Kuchava, Virote Sriuranpong, (unknown), Edvard Zhavrid, (unknown), Laurent Kassalow, Stephanie Jones, Zahid Bashir, (unknown)	12
2	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial breakdown → 2015 ·The Lancet Oncology ·Nick Thatcher, Fred R. Hirsch, Alexander Luft, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, H. Depenbrock, Shivani Nanda, (unknown), Raffael Kurek, Luis Paz‐Ares, Mark A. Socinski	331
3	Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC). 2015 ·Journal of Clinical Oncology ·Mark A. Socinski, Alexander Luft, Aleksandra Szczęsna, W Szafrański, Rinat Galiulin, Beatrix Bálint, Keunchil Park, Martin Reck, H. Depenbrock, Shivani Nanda, Nadia Chouaki, Nick Thatcher	2
4	Efficacy and safety of BCD-021, bevacizumab biosimilar candidate, compared to Avastin: Results of international multicenter randomized double blind phase III study in patients with advanced non-squamous NSCLC. 2015 ·Journal of Clinical Oncology ·(unknown), Sergey Orlov, Olga Burdaeva, М. В. Копп, (unknown), (unknown), (unknown), Daniil Stroyakovskiy, Oleg Gladkov, (unknown), Marina Matrosova, Rinat Galiulin, Pavel Skopin, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Sergei Tjulandin	16
5	A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). 2014 ·Journal of Clinical Oncology ·Nick Thatcher, Fred R. Hirsch, Aleksandra Szczęsna, Tudor–Eliade Ciuleanu, W Szafrański, Mircea Dediu, Rodryg Ramlau, Rinat Galiulin, Beatrix Bálint, György Losonczy, Andrzej Każarnowicz, Keunchil Park, Christian Schumann, Martin Reck, Luis Paz‐Ares, H. Depenbrock, Shivani Nanda, (unknown), Mark A. Socinski	35
6	International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1 2012 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Ihor Vynnychenko, Keunchil Park, Yukito Ichinose, Kaoru Kubota, Fiona Blackhall, Robert Pirker, Rinat Galiulin, Tudor–Eliade Ciuleanu, (unknown), Mircea Dediu, Zsolt Pápai-Székely, Natividad Martínez-Banaclocha, Sheryl McCoy, Bin Yao, (unknown), Francesco Galimi, David R. Spigel	143
7	An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). 2011 ·Journal of Clinical Oncology ·Giorgio V. Scagliotti, Ihor Vynnychenko, Y. Ichinose, (unknown), (unknown), Fiona Blackhall, Robert Pirker, Rinat Galiulin, T-E. Ciuleanu, (unknown), Mircea Dediu, Zsolt Pápai-Székely, Natividad Martínez-Banaclocha, Sarah Westcott McCoy, Bin Yao, (unknown), David R. Spigel	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact